Phase II
After releasing positive topline data from the Phase II study of BAN2401 as a potential treatment for Alzheimer’s disease in July, some of the numbers did not hold up. This morning Biogen and its developmental partner Eisai attempted to provide an update on the information to show that the anti-amyloid plaque treatment still has some life.
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy
MorphoSys AG announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). The study was conducted in patients with moderate to severe RA who had an inadequate response to methotrexate.
BioArctic AB announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
Primary Endpoint was met, with rhC1INH treatment reducing neutrophil gelatinase-associated lipocalin (NGAL), a widely recognized marker of acute renal damage
The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).
Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant prostate cancer (mCRPC).
Preparation of a Phase II program for THN101 in patients with neuropathic pain
KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
PRESS RELEASES